New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDihexa vs Orforglipron

Dihexa vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Dihexa
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
Unknown (limited pharmacokinetic data)
~12 hours (once-daily oral dosing)
Admin Route
Oral, SubQ, Topical
Oral
Research
Typical Dose
5–10 mg
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Daily
Once daily
Key Benefits
  • Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
  • Enhances memory and learning
  • May reverse cognitive decline
  • Improves neuroplasticity and executive function
  • Long-lasting cognitive benefits from short courses
  • Potential therapeutic agent for Alzheimer's
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Headache
  • Irritability
  • Brain fog during washout period
  • Unknown long-term effects (insufficient data)
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With